BEIJING, June 16 (Reuters) – Novo Nordisk plans to seek Chinese regulatory approval for its weight-loss pill "very soon," CEO Mike Doustdar said Tuesday, in a move to catch up with rival Eli Lilly in
(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)